Below are the most recent publications written about "Prednisone" by people in Profiles.
-
Karmali R, Galvez C, Hamadani M, Gordon L, Winter J, Ma S, Nelson V, Fenske TS, Shah NN, Jagadeesh D, Klein A, Helenowski I, Chen R, Mi X, Petrich A, Evens AM, Pro B. A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen. Blood Adv. 2024 04 09; 8(7):1612-1620.
-
Vaishampayan UN, Keessen M, Dreicer R, Heath EI, Buchler T, ?rkosy PF, Cs?szi T, Wiechno P, Kopyltsov E, Orlov SV, Plekhanov A, Smagina M, Varlamov S, Shore ND. A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer. Eur J Cancer. 2024 05; 202:114007.
-
Butkus JM, Sagalow ES, Alfonsi S, Riordan J, Zhan T, McGettigan B, Fisher K, Rosen D, Boon M, Huntley C. Prednisone Decreases Opioid Use in Adults Undergoing Benign Oropharyngeal Surgery. Otolaryngol Head Neck Surg. 2024 02; 170(2):405-413.
-
Broderick A, Labriola MK, Shore N, Armstrong AJ. Foreign accent syndrome as a heralding manifestation of transformation to small cell neuroendocrine prostate cancer. BMJ Case Rep. 2023 Jan 30; 16(1).
-
Fischer R, Porter K, Donovan JM, Scavina MT, Armstrong N, Denger B, Hasham S, Peay H. A Mixed-Method Study Exploring Patient-Experienced and Caregiver-Reported Benefits and Side Effects of Corticosteroid Use in Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2023; 10(4):593-613.
-
Shore N, Mellado B, Shah S, Hauke R, Costin D, Adra N, Cullberg M, Teruel CF, Morris T. A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2023 04; 21(2):278-285.
-
Savage KJ, Horwitz SM, Advani R, Christensen JH, Domingo-Domenech E, Rossi G, Morschhauser F, Alpdogan O, Suh C, Tobinai K, Shustov A, Trneny M, Yuen S, Zinzani PL, Tr?mper L, Ilidge T, O'Connor OA, Pro B, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Iyer S. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. Blood Adv. 2022 10 11; 6(19):5550-5555.
-
Asma A, Ulusaloglu AC, Shrader MW, Mackenzie WG, Heinle R, Scavina M, Howard JJ. No difference in postoperative complication rates or cardiopulmonary function for early versus late scoliosis correction in Duchenne muscular dystrophy. Spine Deform. 2022 11; 10(6):1429-1436.
-
Hong J, Johnson WT, Kartan S, Gonsalves AS, Fenkel JM, Gong JZ, Porcu P. Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD). Curr Oncol. 2021 12 02; 28(6):5067-5072.
-
Sartor O, George D, Tombal B, Agarwal N, Higano CS, Sternberg CN, Miller K, Jiao X, Guo H, Sandstr?m P, Bruno A, Verholen F, Saad F, Shore N. Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. Future Oncol. 2022 Jan; 18(1):35-45.